B
Bassel Elzorkany
Researcher at Cairo University
Publications - 30
Citations - 1149
Bassel Elzorkany is an academic researcher from Cairo University. The author has contributed to research in topics: Medicine & Rheumatoid arthritis. The author has an hindex of 8, co-authored 26 publications receiving 870 citations.
Papers
More filters
Journal ArticleDOI
Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)
Maxime Dougados,Martin Soubrier,Anna Antunez,Peter V. Balint,Alejandro Balsa,Maya H Buch,Maya H Buch,Gustavo Casado,Jacqueline Detert,Bassel Elzorkany,Paul Emery,Paul Emery,Najia Hajjaj-Hassouni,Masayoshi Harigai,Shue Fen Luo,Reka Kurucz,Gabriel Maciel,Emilio Martin Mola,Carlomaurizio Montecucco,Iain B. McInnes,Helga Radner,Josef S Smolen,Yeong Wook Song,Harald E. Vonkeman,Kevin L. Winthrop,Jonathan Kay +25 more
TL;DR: In this multinational sample of rheumatoid arthritis patients, variability among countries was wide, not only in prevalence but also in compliance with recommendations for preventing and managing these comorbidities.
Journal ArticleDOI
Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study
Anna Molto,Adrien Etcheto,Désirée van der Heijde,Robert Landewé,Filip Van den Bosch,Wilson Bautista Molano,Rubén Burgos-Vargas,Peter P. Cheung,Eduardo Collantes-Estevez,Atul Deodhar,Bassel Elzorkany,Shandor Erdes,Jieruo Gu,Najia Hajjaj-Hassouni,Uta Kiltz,Tae-Hwan Kim,Mitsumasa Kishimoto,Shue Fen Luo,Pedro Machado,Pedro Machado,Walter P. Maksymowych,José A. Maldonado-Cocco,Helena Marzo-Ortega,Carlomaurizio Montecucco,Salih Ozgocmen,Floris A. van Gaalen,Maxime Dougados +26 more
TL;DR: Rigorous application of systematic evaluation of comorbidities may permit earlier detection of previously unknown risk factors, which may ultimately result in an improved outcome of patients with SpA.
Journal ArticleDOI
Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis
Uta Kiltz,Désirée van der Heijde,Annelies Boonen,Nurullah Akkoc,Wilson Bautista-Molano,Ruben Burgos-Vargas,James Cheng-Chung Wei,Praveena Chiowchanwisawakit,Maxime Dougados,M. Tuncay Duruoz,Bassel Elzorkany,Inna Gaydukova,Lianne S. Gensler,Michele Gilio,Simeon Grazio,Jieruo Gu,Robert D. Inman,Tae-Jong Kim,Victoria Navarro-Compán,Helena Marzo-Ortega,Salih Ozgocmen,Fernando Pimentel Dos Santos,Michael Schirmer,Simon Stebbings,Filip Van den Bosch,Astrid van Tubergen,Juergen Braun +26 more
TL;DR: The ASAS HI proved to be valid, reliable and responsive and can be used to evaluate the impact of SpA and its treatment on functioning and health.
Journal ArticleDOI
Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study.
Clementina López-Medina,Clementina López-Medina,Anna Molto,Joachim Sieper,Tuncay Duruöz,Uta Kiltz,Bassel Elzorkany,Najia Hajjaj-Hassouni,Ruben Burgos-Vargas,José A. Maldonado-Cocco,Nelly Ziade,Meghna Gavali,Victoria Navarro-Compán,Shue Fen Luo,Sara Monti,Kim Tae-Jong,Mitsumasa Kishimoto,Fernando Pimentel-Santos,Jieruo Gu,Ruxandra Elena Schiotis,Floris A. van Gaalen,Pál Géher,Marina Magrey,Sebastian E. Ibáñez Vodnizza,Wilson Bautista-Molano,Walter P. Maksymowych,Pedro Machado,Pedro Machado,Pedro Machado,Robert Landewé,Désirée van der Heijde,Maxime Dougados +31 more
TL;DR: In this paper, a cross-sectional study with 24 participating countries was conducted to characterize peripheral musculoskeletal involvement in patients with spondyloarthritis (SpA) including psoriatic arthritis (PsA), across the world.
Journal ArticleDOI
An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS
Anna Molto,Laure Gossec,Bhowmik Meghnathi,Robert Landewé,Désirée van der Heijde,Pamir Atagündüz,Bassel Elzorkany,Nurullah Akkoc,Uta Kiltz,Jieruo Gu,James Cheng-Chung Wei,Maxime Dougados +11 more
TL;DR: The ASAS consensus was to define clinically important worsening as an increase in ASDAS of at least 0.9 points, which resulted in an ASDAS-based cut-off value defining clinical important worsening in axSpA for use in trials.